Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors

1996 ◽  
Vol 108 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Hirotaka Iwase ◽  
Jill M. Greenman ◽  
Diana M. Barnes ◽  
Shirley Hodgson ◽  
Lynda Bobrow ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Sequence Variants ◽  
Breast Cancer Patients

scholarly journals Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Young-Joon Kang ◽  
Han-Byoel Lee ◽  
Yun Gyoung Kim ◽  
JaiHong Han ◽  
Yumi Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Prognostic Factor ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Receptor Expression ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
End Point

Objective. While the value of Ki-67 has been recognized in breast cancer, controversy also exists. The goal of this study is to show the prognostic value of Ki-67 according to progesterone receptor (PgR) expression in patients who have estrogen receptor- (ER-) positive, human epidermal growth factor receptor 2- (HER2-) negative early breast cancer. Methods. The records of nonmetastatic invasive breast cancer patients who underwent surgery at a single institution between 2009 and 2012 were reviewed. Primary end point was recurrence-free survival (RFS), and secondary end point was overall survival (OS). Ki-67 and PgR were assessed with immunohistochemistry for the tumor after surgery. Results. A total of 1848 patients were enrolled in this study. 223 (12%) patients had high (≥10%) Ki-67, and 1625 (88%) had low Ki-67 expression. Significantly worse RFS and OS were observed in the high vs. low Ki-67 expression only when the PgR was low (<20%) (p<0.001 and 0.005, respectively, for RFS and OS). There was no significant difference in RFS and OS according to Ki-67 when the PgR was high (p=0.120 and 0.076). RFS of four groups according to high/low Ki-67 and PgR expression was compared. The low PgR and high Ki-67 expression group showed worst outcome among them (p<0.001). In a multivariate analysis, high Ki-67 was an independent prognostic factor when the PgR was low (HR 3.05; 95% CI 1.50–6.19; p=0.002). Conclusions. Ki-67 had a value as a prognostic factor only under low PgR expression level in early breast cancer. PgR should be considered in evaluating the prognosis of breast cancer patients using Ki-67.

Review of Estrogen Receptor, Progesterone Receptor, and HER-2/neu Immunohistochemistry Impacts on Treatment for a Small Subset of Breast Cancer Patients Transferring Care to Another Institution

2013 ◽  
Vol 137 (11) ◽  
pp. 1660-1663 ◽  
Author(s):  
Julie M. Jorns ◽  
Patrick Healy ◽  
Lili Zhao
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Treatment Recommendation ◽  
Small Subset ◽  
Breast Cancer Patients ◽  
Number Of Patients ◽  
Her 2 ◽  
Pathology Review

Context.—Estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu studies are variably submitted for pathology review but are influential in treatment choices for breast cancer patients seeking second opinion or transferring care. Objective.—To determine the frequency of interinstitutional discordance for the interpretation of ER/PR and HER-2/neu immunohistochemical slides and assess the resulting clinical significance. Design.—One thousand one hundred thirty-nine ER, 1111 PR, and 663 HER-2/neu immunohistochemistry stains from 1139 cases were reviewed at contributing and referral centers and compared for concordance and clinical impact of discordance. Results.—Interinstitutional concordance for individual stains was excellent (ER: κ = 0.93; PR: κ = 0.90; HER-2/neu: κ = 0.93). One hundred four (9.1%) had interinstitutional discordance in 1 or more stains; however, the majority of the discordance was clinically insignificant. Seven patients (0.6%) had a clinically significant change in treatment recommendation based on review and 2 (0.2%) had interpretation changes that would likely have resulted in treatment change had they not already completed therapy. Two patients (0.2%) had change in treatment despite concordant interpretations. Conclusions.—Overall, there was excellent interinstitutional concordance for pathology review of ER, PR, and HER-2/neu immunohistochemistry stains. However, a small but significant number of patients (0.8%) received potential benefit from review, justifying inclusion of these slides along with other pathology slides to be reviewed for all breast cancer patients being seen at another institution who have not yet completed hormonal and/or chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document